Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Intranasal administration of spike-specific mRNA-LNP confers more protection than the intramuscular route against SARS-CoV-2

Articles in Press

Document Type : Original Article

Authors
Mohsen Abdoli 1
Hoorieh Soleimanjahi 1
Sara Soudi 2
Asghar Abdoli 3
1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
10.22038/ijbms.2026.94328.20333
Abstract
Objective(s): Intranasal vaccination mimics natural infection and induces mucosal immunity against respiratory viruses. This study compared the immunogenicity and protective efficacy of a nucleoside-modified messenger RNA (mRNA) encoding the SARS-CoV-2 spike protein, encapsulated in lipid nanoparticles (LNPs), administered via intranasal (I.N) versus intramuscular (I.M) routes.
Materials and Methods: BALB/c mice received mRNA-LNP vaccines at 1, 5, or 10 µg doses intramuscularly. Antibody responses (Immunoglobulin G/IgA [IgG/IgA]), neutralization titers (conventional virus neutralization test [cVNT]), and interferon-gamma (IFN-γ) responses were assessed to select the optimal dose. The selected 5 µg dose was then administered to mice and Syrian hamsters via I.N or I.M routes. Post-challenge, lung viral loads (50% Tissue Culture Infectious Dose [TCID₅₀]/ml) and weight changes were evaluated.
Results: The 5 µg dose induced robust humoral and cellular immunity (cVNT >5 log₂). Intranasal delivery elicited strong spike-specific IgA in nasal washes. Although I.M vaccination produced higher serum neutralizing titers (51.2 vs. 22.0), I.N vaccination conferred superior protection with a 4-log reduction in lung viral load (~10¹ TCID₅₀/ml) versus I.M and controls (~10² TCID₅₀/ml). I.N-vaccinated hamsters were completely protected from weight loss, whereas I.M-vaccinated animals showed mild weight reduction (~1%).
Conclusion: Intranasal mRNA-LNP administration elicits potent mucosal and systemic immunity and provides superior protection against SARS-CoV-2 challenge compared to I.M vaccination, underscoring its promise as a transformative strategy for respiratory virus vaccines.
Keywords
COVID-19 vaccines
Intranasal administration
Lipid Nanoparticles
mRNA vaccines
Mucosal immunity
SARS-CoV-2
Subjects
1. Jin J, Agarwala N, Kundu P, Harvey B, Zhang Y, Wallace E, Chatterjee N. Individual and community-level risk for COVID-19 mortality in the United States. Nat Med 2021;27:264-269.
2. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect 2020;9:313-319.
3. Teo SP. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract 2022;35:947-951.
4. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: A key target for antivirals. Expert Opin Ther Targets 2017;21:131-143.
5. Ng WH, Liu X, Mahalingam S. Development of vaccines for SARS-CoV-2. F1000Res 2020;9: F1000 Faculty Rev-991.
6. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83-100.
7. Verdecia M, Kokai-Kun JF, Kibbey M, Acharya S, Venema J, Atouf F. COVID-19 vaccine platforms: Delivering on a promise? Hum Vaccin Immunother 2021;17:2873-2893.
8. Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther 2022;7:94.
9. Dhama K, Dhawan M, Tiwari R, Emran TB, Mitra S, Rabaan AA, et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother 2022;18:2045853.
10. Baldeon Vaca G, Meyer M, Cadete A, Hsiao CJ, Golding A, Jeon A, et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Sci Adv 2023;9:eadh1655.
11. Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: A biotech and industrial perspective. NPJ Vaccines 2020;5:11.
12. Mirtaleb MS, Falak R, Heshmatnia J, Bakhshandeh B, Taheri RA, Soleimanjahi H, Zolfaghari Emameh R. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations. Int Immunopharmacol 2023;117:109934.
13. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci 2021;110:997-1001.
14. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A 1989;86:6077-6081.
15. Kong W, Wei Y, Dong Z, Liu W, Zhao J, Huang Y, et al. Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA. J Nanobiotechnology 2024;22:553.
16. Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv 2016;7:319-34.
17. Pascolo S. Synthetic messenger RNA-based vaccines: From scorn to hype. Viruses 2021;13:270.
18. Zamani P, Mashreghi M, Rezazade Bazaz M, Zargari S, Alizadeh F, Dorrigiv M, et al. Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates. J Control Release 2023;360:316-334.
19. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020;586:567-571.
20. Yahyaei S, Abdoli A, Jamali A, Teimoori A, Arefian E, Eftekhari Z, Jamur P. Targeting respiratory viruses: The efficacy of intranasal mrna vaccination in generating protective mucosal and systemic immunity against influenza a (H1N1). Influenza Other Respir Viruses 2025;19:e70093.
21. Zhuang X, Qi Y, Wang M, Yu N, Nan F, Zhang H, et al. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines (Basel) 2020;8:123.
22. Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther 2020;28:1569-1584.
23. Najafi N, Soleimanjahi H, Moghaddam-Banaem L, Raoufy MR, Shahali S, Kazemnejad A, Nasiri Z. Humoral immunogenicity assessment after receiving three types of SARS-CoV-2 vaccine. Sci Rep 2023;13:20213.
24. Reynolds SP, Edwards JH, Jones KP, Davies BH. Immunoglobulin and antibody levels in bronchoalveolar lavage fluid from symptomatic and asymptomatic pigeon breeders. Clin Exp Immunol 1991;86:278-285.
25. Shafaati M, Bagherzadeh K, Lotfinia M, Karimi H, Teimoori A, Razazian M, et al. The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies. Heliyon 2023;9:e14108.
26. Miller J, Ulrich R. On the analysis of psychometric functions: the Spearman-Kärber method. Percept Psychophys 2001;63:1399-1420.
27. Abdoli M, Shafaati M, Ghamsari LK, Abdoli A. Intranasal administration of cold-adapted live-attenuated SARS-CoV-2 candidate vaccine confers protection against SARS-CoV-2. Virus Res 2022;319:198857.
28. Kang H, Yan M, Yu Q, Yang Q. Characteristics of nasal-associated lymphoid tissue (NALT) and nasal absorption capacity in chicken. PLoS One 2013;8:e84097.
29. Hall K, Blair Zajdel ME, Blair GE. Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochem J 2010;431:321-336.
30. Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios RV, Rodríguez-Guilarte L, Opazo MC, et al. SARS-CoV-2: Immune response elicited by infection and development of vaccines and treatments. Front Immunol 2020;11:569760.
31.    McCormick AA, Shakeel A, Yi C, Kaur H, Mansour AM, Bakshi CS. Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge. PLoS One 2018;13:e0194614.
32. Butler SE, Crowley AR, Natarajan H, Xu S, Weiner JA, Lee J, et al. Features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals. medRxiv 2020; 2020.08.05.20168971.
33. Bleier BS, Ramanathan M, Jr., Lane AP. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol Head Neck Surg 2021;164:305-307.
34. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017;543:248-51.
35. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against zika virus infection. Cell 2017;168:1114-25.e10.
36. Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2017;2:29.
37. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 2017;390:1511-1120.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 28 July 2026